Single-visit versus multiple-visit cervical cancer screen-and-treat for women with HIV in Foumban, Cameroon
Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform
This project will test whether doing all cervical cancer screening and treatment in one clinic visit or spreading it over multiple visits helps more women living with HIV complete care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1422 (estimated) |
| Ages | 25 Years to 49 Years |
| Sex | Female |
| Sponsor | Institut de Recherche pour le Developpement Government |
| Locations | 1 site (Foumban) |
| Trial ID | NCT07177170 on ClinicalTrials.gov |
What this trial studies
This interventional program compares a single-visit screen-and-treat approach with a differentiated multiple-visit delivery model for HPV-based cervical cancer screening among women living with HIV at a district hospital. Enrolled participants (women on antiretroviral therapy who live in the hospital catchment area) will receive HPV testing, visual triage, and treatment when indicated, and the study will measure completion at each step of the screening cascade. The study also examines implementation outcomes such as feasibility and acceptability and includes sub-studies to refine the differentiated delivery model. The work is conducted at Foumban hospital in Cameroon with partners from regional and international research institutions.
Who should consider this trial
Good fit: Women living with HIV who are receiving antiretroviral therapy and live in the department served by Foumban hospital, who are not pregnant and have not had a recent hysterectomy or recent cervical treatment, are ideal candidates.
Not a fit: Women who are pregnant, have had a hysterectomy, received treatment for a cervical lesion within the past 12 months, have active pelvic infection, or cannot attend required visits are excluded and unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the preferred approach could increase the number of women who complete screening and receive timely treatment, lowering future cervical cancer cases and deaths among women living with HIV.
How similar studies have performed: A large South African trial supported a single-visit screen-and-treat approach, though the applicability of that result can vary by local resources and logistics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HIV infection * receiving antiretroviral therapy * living in the department of the study hospital Exclusion Criteria: * ongoing pregnancy * hysterectomy * treatment of cervical lesion in the past 12 months * Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.); * Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if * menstrual bleeding * post-partum (\<12 weeks after delivery) * clinicla signs of cervical or pelvic infection
Where this trial is running
Foumban
- Foumban hospital — Foumban, Cameroon (Recruiting)
Study contacts
- Principal investigator: Joëlle Sobngwi, MD, PhD — RSD Institute
- Study coordinator: Andre-Pascal Goura, MD
- Email: cdpoptitri@gmail.com
- Phone: +227679336464
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.